Panagora Asset Management’s Theravance Biopharma TBPH Stock Holding History

Panagora Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-103,049	Closed	-$1.04M	–	1508
2022 Q3	$1.04M	Hold	103,049	–	–	0.01%	843
2022 Q2	$934K	Sell	103,049 -167,642	-62%	-$1.54M	0.01%	905
2022 Q1	$2.59M	Buy	270,691 +11,296	+4%	+$111K	0.01%	611
2021 Q4	$2.87M	Buy	259,395 +83,721	+48%	+$730K	0.02%	537
2021 Q3	$1.3M	Sell	175,674 -3,526	-2%	-$39.4K	0.01%	851
2021 Q2	$2.6M	Sell	179,200 -7,915	-4%	-$149K	0.01%	634
2021 Q1	$3.82M	Buy	187,115 +2,128	+1%	+$40.4K	0.02%	538
2020 Q4	$3.29M	Buy	184,987 +90,026	+95%	+$1.62M	0.02%	540
2020 Q3	$1.4M	Buy	94,961 +106	+0.1%	+$1.99K	0.01%	776
2020 Q2	$1.99M	Buy	+94,855	New	+$2.44M	0.01%	673
2019 Q2	–	Sell	-3,111	Closed	-$71K	–	2673
2019 Q1	$71K	Hold	3,111	–	–	﹤0.01%	1966
2018 Q4	$80K	Hold	3,111	–	–	﹤0.01%	1864
2018 Q3	$102K	Hold	3,111	–	–	﹤0.01%	1856
2018 Q2	$70K	Hold	3,111	–	–	﹤0.01%	1962
2018 Q1	$75K	Hold	3,111	–	–	﹤0.01%	1925
2017 Q4	$87K	Hold	3,111	–	–	﹤0.01%	1918
2017 Q3	$107K	Sell	3,111 -68,722	-96%	-$2.25M	﹤0.01%	1870
2017 Q2	$2.86M	Buy	71,833 +908	+1%	+$34.9K	0.01%	741
2017 Q1	$2.61M	Sell	70,925 -1,642	-2%	-$52.5K	0.01%	784
2016 Q4	$2.31M	Sell	72,567 -93,014	-56%	-$2.89M	0.01%	842
2016 Q3	$6M	Sell	165,581 -46,534	-22%	-$1.3M	0.03%	507
2016 Q2	$4.81M	Buy	212,115 +34,203	+19%	+$739K	0.02%	567
2016 Q1	$3.35M	Buy	177,912 +72,418	+69%	+$1.18M	0.02%	695
2015 Q4	$1.73M	Buy	105,494 +36,188	+52%	+$574K	0.01%	868
2015 Q3	$762K	Buy	69,306 +7,298	+12%	+$92.9K	﹤0.01%	1155
2015 Q2	$807K	Buy	62,008 +19,312	+45%	+$300K	﹤0.01%	1178
2015 Q1	$741K	Buy	42,696 +13,888	+48%	+$255K	﹤0.01%	1179
2014 Q4	$430K	Sell	28,808 -8,319	-22%	-$145K	﹤0.01%	1341
2014 Q3	$856K	Sell	37,127 -133	-0.4%	-$3.86K	﹤0.01%	1114
2014 Q2	$1.19M	Buy	+37,260	New	+$1.12M	0.01%	1035

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Panagora Asset Management's TBPH Position: Q4 2022 in Review

Panagora Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 103,049 shares — an estimated $1.04M sold.

Panagora Asset Management first reported a position in TBPH in Q2 2014 and held it in 30 quarters. The position peaked at $6M in Q3 2016. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

Panagora Asset Management reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
Panagora Asset Management sold 103,049 Theravance Biopharma shares in Q4 2022, an estimated $1.04M.
Panagora Asset Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 30 quarters.
Panagora Asset Management's Theravance Biopharma position peaked at $6M in Q3 2016.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Panagora Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.